Volume 17, Number 4Case ReviewSorafenib-induced Scrotal EczemaSelahattin CaliskanSorafenib is an orally active, small-molecule multikinase inhibitor that blocks tumor cell proliferation and angiogenesis. Studies have shown that it is a highly potent, selective inhibitor of vascular endothelial growth factor receptors 2 and 3, platelet-derived growth factor-β, RAF, FLT-3, and c-Kit. This drug was recently approved for the treatment of metastatic renal cell carcinoma and hepatocellular carcinoma. We report a case of a patient treated with sorafenib for metastatic renal cell carcinoma who developed scrotal eczema. [Rev Urol. 2015;17(4):250-251 doi: 10.3909/riu0648] © 2016 MedReviews®, LLCSorafenibScrotal eczemaHand-foot skin reaction
Volume 18, Number 1Case ReviewUreteral Stone Associated With a Middle Blind Ending of a Bifid UreterSelahattin CaliskanA blind-ending bifid ureter is an anatomic variant of ureteral duplications. There are three forms of blind-ending bifid ureter, classified depending on their location. A proximal blind-ending bifid ureter is the most common subtype of this congenital anomaly. Most patients are asymptomatic and only show symptoms after the complication has occurred. These complications include stone formation, vesicoureteric reflux, and ureteral tumor. Intravenous urography is usually used to diagnose bifid ureter; voiding cystourethrography, photofluoroscopy, cineroentgenography, cystoscopy with retrograde pyelography, computed tomography (CT), multidetector CT, and magnetic resonance urographies are other imaging methods used. This is a case of a ureteral stone associated with a middle blind ending of a bifid ureter. [Rev Urol. 2016;18(1):54-56 doi: 10.3909/riu0688] © 2016 MedReviews®, LLCBlind-ending bifid ureterUreteral duplicationUreteral stoneUreteroscopic